Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04270175 · ClinicalTrials.gov registry record · Phase 2
Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab
A Phase 2 study of AL Amyloidosis and Amyloid, sponsored by Weill Medical College of Cornell University.
- Active
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
- 4
- Study locations
NCT04270175: Active Phase 2 study of AL Amyloidosis and Amyloid, sponsored by Weill Medical College of Cornell University.
NCT04270175 is a Phase 2 study of AL Amyloidosis and Amyloid that is active but no longer recruiting, run by Weill Medical College of Cornell University. The registered enrollment target is 15 participants, below the 423-participant average among 15 other AL Amyloidosis trials with a reported enrollment target (96% lower). The trial reports 4 study locations across 4 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04270175, a Phase 2 study of AL Amyloidosis and Amyloid, is active but no longer recruiting, sponsored by Weill Medical College of Cornell University.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
- 4
- Study locations
Study Summary
This study will test the hypothesis that in patients with previous daratumumab exposure, combination therapy of daratumumab, pomalidomide, and dexamethasone (DPd) will yield higher complete remission (CR) rates in relapsed/refractory amyloidosis than historical pomalidomide/dexamethasone treatment.
Primary Outcome
Overall complete hematologic response rate will be defined as percentage of participants who achieve Complete Hematologic Response
Conditions Studied
Interventions
- DRUG Dexamethasone
- DRUG Pomalidomide
- DRUG Daratumumab SC
Study Locations (4)
California
- Stanford University - Palo Alto
Massachusetts
- Boston University Medical Center - Boston
New York
- Weill Cornell Medicine - Multiple Myeloma Center - New York
Wisconsin
- Medical College of Wisconsin - Milwaukee
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2021-04-14 |
| Est. Completion | 2028-01 |
| Phase | Phase 2 |
What the registry record for NCT04270175 still lists
NCT04270175 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 423-participant average among 15 other AL Amyloidosis trials with a reported enrollment target (96% lower).
The record links to 3 conditions, with AL Amyloidosis appearing as the primary indexed condition, and to 3 interventions - of which Dexamethasone is the first listed.
NCT04270175 reports a single indexed study location in California, Massachusetts, New York.
Frequently Asked Questions
What is clinical trial NCT04270175 about?
NCT04270175 is a clinical study titled "Daratumumab, Pomalidomide, and Dexamethasone (DPd) in Relapsed/Refractory Light Chain Amyloidosis Patients Previously Exposed to Daratumumab". This study will test the hypothesis that in patients with previous daratumumab exposure, combination therapy of daratumumab, pomalidomide, and dexamethasone (DPd) will yield higher complete remission (CR) rates in relapsed/refractory amyloidosis than historical pomalidomide/dexamethasone treatment.
What is the current status of trial NCT04270175?
This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2021-04-14. Estimated completion is 2028-01.
What conditions does trial NCT04270175 study?
This clinical trial studies the following conditions: AL Amyloidosis, Amyloid, Refractory AL Amyloidosis.
What interventions are being tested in trial NCT04270175?
The interventions under investigation include: Dexamethasone (DRUG), Pomalidomide (DRUG), Daratumumab SC (DRUG).
Who is sponsoring clinical trial NCT04270175?
This trial is sponsored by Weill Medical College of Cornell University, which has 701 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04270175 being conducted?
This trial has 4 study locations across California, Massachusetts, New York, Wisconsin. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for AL Amyloidosis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04270175's enrollment target sits among peer trials
15 15th of 15 higher than 1 of 15 other AL Amyloidosis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other AL Amyloidosis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Daratumumab Maintenance Therapy for Improving Survival in Patients With Light Chain Amyloidosis, EMILIA Trial
RECRUITING · Phase 2
-
Siltuximab to Decrease Symptom Burden After Autologous Stem Cell Transplantation for Patients With Multiple Myeloma and AL Amyloidosis
ACTIVE NOT RECRUITING · Phase 2
-
Ixazomib Maintenance Study in Patients With AL Amyloidosis
ACTIVE NOT RECRUITING · Phase 2
-
Bendamustine and Dexamethasone in Patients With Relapsed AL Amyloidosis
COMPLETED · Phase 2
-
Ohio State University Multiple Myeloma and Amyloidosis Data Registry and Sample Resource
RECRUITING
-
Phase 1/2a Study of Belantamab Mafodotin in Relapsed or Refractory AL Amyloidosis
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI